These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26338776)

  • 1. In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization.
    Kamola PJ; Kitson JD; Turner G; Maratou K; Eriksson S; Panjwani A; Warnock LC; Douillard Guilloux GA; Moores K; Koppe EL; Wixted WE; Wilson PA; Gooderham NJ; Gant TW; Clark KL; Hughes SA; Edbrooke MR; Parry JD
    Nucleic Acids Res; 2015 Oct; 43(18):8638-50. PubMed ID: 26338776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
    Burel SA; Hart CE; Cauntay P; Hsiao J; Machemer T; Katz M; Watt A; Bui HH; Younis H; Sabripour M; Freier SM; Hung G; Dan A; Prakash TP; Seth PP; Swayze EE; Bennett CF; Crooke ST; Henry SP
    Nucleic Acids Res; 2016 Mar; 44(5):2093-109. PubMed ID: 26553810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus.
    Liang XH; Sun H; Nichols JG; Crooke ST
    Mol Ther; 2017 Sep; 25(9):2075-2092. PubMed ID: 28663102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells.
    Yoshida T; Naito Y; Yasuhara H; Sasaki K; Kawaji H; Kawai J; Naito M; Okuda H; Obika S; Inoue T
    Genes Cells; 2019 Dec; 24(12):827-835. PubMed ID: 31637814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
    Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
    Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.
    Kasuya T; Hori S; Watanabe A; Nakajima M; Gahara Y; Rokushima M; Yanagimoto T; Kugimiya A
    Sci Rep; 2016 Jul; 6():30377. PubMed ID: 27461380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
    Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP
    Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
    Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
    Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy.
    Watt AT; Swayze G; Swayze EE; Freier SM
    Nucleic Acid Ther; 2020 Aug; 30(4):215-228. PubMed ID: 32125928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LNA-antisense rivals siRNA for gene silencing.
    Jepsen JS; Wengel J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA Reduction and Hepatotoxic Potential Caused by Non-Gapmer Antisense Oligonucleotides.
    Hori SI; Mitsuoka Y; Kugimiya A
    Nucleic Acid Ther; 2019 Feb; 29(1):44-50. PubMed ID: 30508397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice.
    Hagedorn PH; Pontoppidan M; Bisgaard TS; Berrera M; Dieckmann A; Ebeling M; Møller MR; Hudlebusch H; Jensen ML; Hansen HF; Koch T; Lindow M
    Nucleic Acids Res; 2018 Jun; 46(11):5366-5380. PubMed ID: 29790953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Computationally Evaluated Target Specificity in the Hepatotoxicity of Gapmer Antisense Oligonucleotides.
    Kasuya T; Kugimiya A
    Nucleic Acid Ther; 2018 Oct; 28(5):312-317. PubMed ID: 30095329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine-tuning of ENA gapmers as antisense oligonucleotides for sequence-specific inhibition.
    Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
    Oligonucleotides; 2007; 17(3):291-301. PubMed ID: 17854269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gapmer Antisense Oligonucleotides Containing 2',3'-Dideoxy-2'-fluoro-3'-C-hydroxymethyl-β-d-lyxofuranosyl Nucleotides Display Site-Specific RNase H Cleavage and Induce Gene Silencing.
    Danielsen MB; Lou C; Lisowiec-Wachnicka J; Pasternak A; Jørgensen PT; Wengel J
    Chemistry; 2020 Jan; 26(6):1368-1379. PubMed ID: 31682037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins.
    Zhang L; Vickers TA; Sun H; Liang XH; Crooke ST
    Nucleic Acids Res; 2021 Mar; 49(5):2721-2739. PubMed ID: 33577678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages.
    Wan WB; Migawa MT; Vasquez G; Murray HM; Nichols JG; Gaus H; Berdeja A; Lee S; Hart CE; Lima WF; Swayze EE; Seth PP
    Nucleic Acids Res; 2014 Dec; 42(22):13456-68. PubMed ID: 25398895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides.
    Dieckmann A; Hagedorn PH; Burki Y; Brügmann C; Berrera M; Ebeling M; Singer T; Schuler F
    Mol Ther Nucleic Acids; 2018 Mar; 10():45-54. PubMed ID: 29499955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XRN2 is required for the degradation of target RNAs by RNase H1-dependent antisense oligonucleotides.
    Hori S; Yamamoto T; Obika S
    Biochem Biophys Res Commun; 2015 Aug; 464(2):506-11. PubMed ID: 26159921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.